FUNDAMENTAL AND CLINICAL STUDIES IN NEONATES AND INFANTS ON LATAMOXEF

DOI Web Site PubMed
  • NAKAZAWA SUSUMU
    Department of Pediatrics, Tokyo Ebara Municipal Hospital Department of Pediatrics, School of Medicine, Showa University
  • SATO HAJIME
    Department of Pediatrics, Tokyo Ebara Municipal Hospital Department of Pediatrics, School of Medicine, Showa University
  • NIINO KENJI
    Department of Pediatrics, Tokyo Ebara Municipal Hospital Department of Pediatrics, School of Medicine, Showa University
  • HIRAMA YUICHI
    Department of Pediatrics, Tokyo Ebara Municipal Hospital Department of Pediatrics, School of Medicine, Showa University
  • NARITA AKIRA
    Department of Pediatrics, Tokyo Ebara Municipal Hospital Department of Pediatrics, School of Medicine, Showa University
  • NAKAZAWA SHIN-ICHI
    Department of Pediatrics, Tokyo Ebara Municipal Hospital Department of Pediatrics, School of Medicine, Showa University
  • CHIKAOKA HIDEJIRO
    Department of Pediatrics, Takatsu Central Hospital

Bibliographic Information

Other Title
  • 新生児並びに幼若乳児におけるLatamoxefの基礎的, 臨床的検討
  • シンセイジ ナラビニ ヨウジャク ニュウジ ニ オケル Latamoxef ノ

Search this article

Description

1. Fundamental and clinical studies in infants including neonates on latamoxef (LMOX) were carried out, and following results were obtained.<BR>2. In fundamental studies, half-lives of LMOX were 5.79, 4.38 hours, at dose 10 mg/kg by intravenous injection and intravenous drip infusion in neonates, respectively.And urinary excretions were 6.8, 15.6% for 6 hours, respectively.In 28-50 day-old neonates, half-lives were 2.26-4.3 hours at dose 20mg/kg, and urinary excretions were renged from 14.3 to 37.0%.<BR>3. Clinical results were following.In 8 cases of bronchopneumonia and 2 cases of pertussis, the clinical efficacy rate was 100% at daily dose 38-100 mg/kg twice or third a day by intravenous injection or intravenous drip infusion for 6-9 days duration.<BR>4. All causative organisms (K. pneumoniae 1, S.aureus 1) were eliminated after LMOX 43 or 38 mg/kg/day dose administration.<BR>5. Side effect and laboratory abnormal value were not noticed in all cases. We finally have a conclusion that LMOX should be administered 40-70 mg/kg/day, and given twice or third a day by intravenous injection or intravenous drip infusion.

Journal

Details 詳細情報について

Report a problem

Back to top